CN111363722B - Monoclonal antibody of bacillus thuringiensis Cry2A toxin and application thereof - Google Patents

Monoclonal antibody of bacillus thuringiensis Cry2A toxin and application thereof Download PDF

Info

Publication number
CN111363722B
CN111363722B CN202010350203.9A CN202010350203A CN111363722B CN 111363722 B CN111363722 B CN 111363722B CN 202010350203 A CN202010350203 A CN 202010350203A CN 111363722 B CN111363722 B CN 111363722B
Authority
CN
China
Prior art keywords
cry2a
monoclonal antibody
antibody
toxin
pbst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010350203.9A
Other languages
Chinese (zh)
Other versions
CN111363722A (en
Inventor
刘贤金
李懿航
范荣荣
刘媛
郝佳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Academy of Agricultural Sciences
Original Assignee
Jiangsu Academy of Agricultural Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Academy of Agricultural Sciences filed Critical Jiangsu Academy of Agricultural Sciences
Priority to CN202010350203.9A priority Critical patent/CN111363722B/en
Publication of CN111363722A publication Critical patent/CN111363722A/en
Application granted granted Critical
Publication of CN111363722B publication Critical patent/CN111363722B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1278Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/32Assays involving biological materials from specific organisms or of a specific nature from bacteria from Bacillus (G)
    • G01N2333/325Bacillus thuringiensis crystal protein (delta-endotoxin)

Abstract

The invention discloses a preparation method and application of an antibody for detecting Bt Cry2A toxin, wherein the antibody is obtained by immunizing Balb/c mice, and the antibody has a preservation number of CCTCC NO: c2019188 hybridoma cell secretion; the application also provides a DAS-ELISA detection method based on the antibody, the minimum detection limit of the method is 10.76ng/ml, the cross reaction rate of the Cry1Aa, cry1Ab, cry1Ac, cry1C and Cry1F toxins based on 50 mu g/ml is less than 0.1 percent, the cross reaction rate of the Cry1Aa, cry1Ab, cry1Ac, cry1C and Cry1F toxins based on 50 mu g/ml is 3.2 percent, the specificity is strong, the method can be used for quickly detecting the Cry2A toxin, and the blank in the field of Cry2A toxin detection is filled.

Description

Monoclonal antibody of bacillus thuringiensis Cry2A toxin and application thereof
Technical Field
The invention relates to a monoclonal antibody of a bacillus thuringiensis Cry2A toxin common in transgenic plants and application thereof, which can be used for preparing a kit for detecting the Cry2A toxin common in the transgenic plants, and belongs to the technical field of biology.
Background
Bacillus Thuringiensis (BT), a crystal-producing Bacillus containing many varieties, is a gram-positive bacterium. The BT Cry toxin is widely applied to agricultural production due to the advantages of high specificity to target insects, safety to human, livestock and beneficial organisms, no pollution to the environment and the like, but in recent years, people have increasing worry about the problems of environmental ecological safety and potential safety hazard due to the use of Bt gene-transgenic insect-resistant plants. The detection of transgenic Bt plants is mainly aimed at recombinant DNA and Cry toxin protein.
Currently, generally accepted methods for accurately and specifically detecting a transgenic Bt plant mainly include PCR, real-time PCR, high Performance Liquid Chromatography (HPLC), ELISA, colloidal gold immunochromatography test strips, and the like. However, although the PCR method has high sensitivity and specificity, the expression level of the Cry toxin cannot be determined, and it is additionally time-consuming and requires a specialized instrument to be operated by a professional. For the HPLC determination method, expensive instruments are needed, the cost is high, trained professionals are needed for operation, the pretreatment is complex, the consumed time is long, and the method cannot be used for rapid field detection. The immunological detection method, such as ELISA and colloidal gold immunochromatography test strip, has simple operation, does not need expensive instruments, and can detect the target protein quantitatively or semi-quantitatively in a short time.
Immunological detection techniques are mainly established on the basis of specific reactions of antigens and antibodies, i.e., antigen-antibody reactions, i.e., specific reactions between antigens and antibodies. Immunological assays also exist in both competitive and non-competitive formats. The non-competitive immunoassay technology is a mode superior to the competitive immunoassay technology, and has higher specificity, higher sensitivity and less antigen dosage.
DAS-ELISA (double sandwich ELISA detection) is the most widely used method in Bt Cry toxin detection, where the analyte is sandwiched between a capture antibody and a detection antibody. At present, a plurality of detection methods based on DAS-ELISA are applied to the detection of Cry toxins, such as Cry1Ab, cry1Ac and the like. In 2015, wuaihua and the like screen and obtain dodecapeptide capable of specifically binding Cry2A from phage display dodecapeptide, and an indirect competitive ELISA method for detecting Cry2A toxin is established based on the dodecapeptide. However, due to the presence of the common structure, monoclonal antibodies detected for certain Bt toxins have some cross-reactivity to other toxins. (noda et al development and identification of a sensitive and fast chemical enzyme immunoassay for the detection of genetic modified mail, 2006 Zhang rt ai. Rapid isolation of single-chain antibodies from a human synthetic phase display for the detection of Bacillus thuringiensis (Bt) Cry1B toxin, 2012). Currently, there exists a Cry1 class A detection method (Dongsa et al.production and Characterization of Monoclonal Antibody Broadly recognition Cry1 Toxins by Use of Designed polypeptides as happten, 2016), but no Monoclonal Antibody detection method against Cry2A toxin has been reported.
Disclosure of Invention
Aiming at the problems of long time consumption and cross reaction existing in the detection of the Cry2A toxin, the application provides the Bacillus thuringiensis Cry2A toxin monoclonal antibody, the Cry2A monoclonal antibody is used for DAS-ELISA detection, the cross reaction rate is low, on the premise of coating completion, whether Cry2A exists in a sample can be rapidly detected within 4-5 hours, the detection result shows obvious color change (blue), rapid and accurate detection of the Cry2A toxin is realized, and the time is saved.
The application is realized by adopting the following technical scheme:
the application firstly provides a bacillus thuringiensis Cry2A monoclonal antibody hybridoma cell strain 1D2D11, and the preservation number of the cell strain 1D2D11 is CCTCC NO: c2019188, the preservation unit is China Center for Type Culture Collection (CCTCC), the address: wuhan, china, zip code: 430072, with the collection name: the hybridoma cell strain 1D2D11 has a preservation time of 2019, 10 months and 30 days.
Secondly, the application also provides a new product prepared from the following components with the preservation number of CCTCC NO: the bacillus thuringiensis Cry2A monoclonal antibody is prepared from the hybridoma cell strain 1D2D11 of C2019188.
Third, the present application provides a method comprising the steps of: the application of the Bacillus thuringiensis Cry2A monoclonal antibody prepared from the hybridoma cell strain 1D2D11 of C2019188, namely a DAS-ELISA non-competitive detection method aiming at Bt Cry2A established by utilizing the monoclonal antibody can be used for detecting whether Bt Cry2A genes are carried or remained in leaves of crops in a laboratory or a field, the method breaks through the cross reaction phenomenon of a common structure in non-competitive detection, and can specifically detect a sample with the Bt Cry2A toxin concentration within the range of 0.010763-4 mu g/ml;
the detection method comprises the following specific steps:
(1) Coating the capture antibody: diluting a Cry2A toxin polyclonal antibody (the preparation method is referred to as 'preparation and application analysis of a canine procalcitonin protein polyclonal antibody', wangman, shandong university of agriculture '2019 Master thesis') to 0.5 mu g/ml by using a PBS buffer solution, adding the diluted solution into a 96-well enzyme label plate, adding the solution into the 96-well enzyme label plate at 100 mu l/well, and standing overnight at 4 ℃;
(2) And (3) sealing: the next day the plates were washed 3 times with PBST. Adding 200 μ l of 5% MPBS per well, and incubating at 37 deg.C for 1h;
(3) Adding a sample: PBST is washed for three times, the sample to be tested is diluted by 2 times in CBS buffer solution and then is added into the hole with 100 mul/hole, CBS is used as blank control at the same time, and incubation is carried out for 1h at 37 ℃;
(4) Adding the antibody to be detected: PBST is washed for three times, and 0.5 mu g/ml of CCTCC NO: the Cry2A monoclonal antibody secreted by the hybridoma cell strain 1D2D11 of C2019188 is injected into a mouse, and the collected antibody (100 mu l/hole) after ascites purification is placed in an incubator at 37 ℃ for incubation for 1h;
(5) Adding an enzyme-labeled antibody: the plates were washed 3 times with PBST, 100 μ Ι hrp-labeled goat anti-mouse antibody (1;
(6) Color development: washing the plate for 5 times by PBST, adding TMB color development solution into the micropore of the ELISA plate at a concentration of 100 mu l/hole, and incubating for 15min in an incubator at 37 ℃; whether the sample contains the Cry2A toxin or not can be detected in the range of 0.010763-4 μ g/ml, and the sample shows blue color change.
Fourthly, the application provides a DAS-ELISA kit for detecting Bt Cry2A, which comprises a nucleic acid sequence with a preservation number of CCTCC NO: the hybridoma cell strain 1D2D11 of C2019188 secretes a Bacillus thuringiensis Cry2A monoclonal antibody.
Aiming at the common Bt Cry2A gene in transgenic plants, protoxin is selected as an immune antigen, a Balb/c mouse is immunized, and a positive hybridoma cell strain capable of efficiently secreting monoclonal antibodies is obtained through cell fusion and subclone screening, so that compared with the existing Bacillus thuringiensis Cry2A detection method, the positive hybridoma cell strain has the following advantages and beneficial effects:
(1) The hybridoma cell strain 1D2D11 obtained by the invention has the preservation number of CCTCC NO: the monoclonal antibody secreted by the C2019188 can specifically recognize Bt Cry2A and has the characteristic of detecting transgenic Bt Cry2A protein.
(2) The hybridoma cell strain 1D2D11 obtained by the invention has the preservation number of CCTCC NO: DAS-ELISA detection established by the monoclonal antibody secreted by the C2019188 breaks through common cross reaction phenomenon of common structure in non-competitive detection, can specifically detect Bt Cry2A toxin, and has the lowest detection limit of 10ng.
(3) The hybridoma cell strain 1D2D11 obtained by the invention has the preservation number of CCTCC NO: the monoclonal antibody generated by the C2019188 can be applied to detection and screening of transgenic plants such as Western blotting (Western blotting), DAS-ELISA, indirect ELISA, genetic engineering and the like, has sensitive reaction and short detection time (4-5 h), and has extremely high practical application value.
Drawings
FIG. 1 is a schematic diagram showing the effect of antibody purification;
FIG. 2 is a schematic representation of the specificity of monoclonal antibodies;
FIG. 3 is a schematic diagram of the assay concentration of the optimal capture antibody;
FIG. 4 is a diagram showing a standard curve established by DAS-ELISA at an optimal antibody concentration;
FIG. 5 is a schematic representation of a Cry1B cross-reaction standard curve.
Detailed Description
The present invention is further described with reference to the drawings and the detailed description below, so that those skilled in the art can more clearly understand the technical solutions of the present invention, and the present invention is not limited thereto.
Reagents, instruments, mouse sources to which the following examples refer:
freund's complete adjuvant, freund's incomplete adjuvant, 50% by mass of PEG, HAT, all purchased from Sigma company;
the Cry1Aa, cry1Ab, cry1Ac, cry1B, cry1C and Cry1F proteins are all purchased from Shanghai Youlong Biotech limited;
cry2A protein was purchased from Envirologix, usa;
balb-c mice were purchased from the comparison center of Yangzhou university;
HiTrap Protein G HP was purchased from GE;
mouse myeloma cells sp/20 are provided by the laboratory;
RPMI-1640 medium and fetal bovine serum were purchased from Gibco;
one-component TMB color former (PR 1200) was purchased from Solarbio;
HRP-labeled goat anti-mouse antibody was purchased from KPL company. Other reagents, unless otherwise specified, were obtained commercially.
EXAMPLE 1 immunization of mice and preparation of monoclonal antibodies
1. Immunization of mice
Cry2A protein is emulsified with Freund's complete adjuvant (see product instruction), and 6-8-year-old female Balb-c mice are injected intraperitoneally at a dose of 50 μ g/mouse. Following a booster every 14 days, the Cry2A protein was emulsified with Freund's incomplete adjuvant at a dose of 50. Mu.g/mouse. The titer was measured by tail-off and blood-sampling after one week of each immunization, and the mice with the highest titer (6.4X 10) were selected after no significant increase in titer 5 ) Injecting the mixture into abdominal cavity for impact immunization, and mixing the antigen with normal saline uniformly, wherein the dosage is 50 mu g per mouse.
2. Preparation of monoclonal antibodies
When the titer reaches 640000 times of serum dilution and the OD450 value is greater than 1.0, collecting ascites of a mouse, preparing the mouse monoclonal antibody according to a conventional monoclonal antibody preparation technology (the specific antibody preparation technology refers to Liu Jing et al, preparation and characteristics of the duck skeletal muscle troponin I monoclonal antibody, 2019), and finally obtaining the mouse monoclonal antibody prepared by the cell strain 1D2D 11.
The applicant reserves the hybridoma cell strain named hybridoma cell strain 1D2D11 in 2019, 10 months and 30 days in the chinese typical culture collection at address: wuhan university in Wuhan, china, zip code: 430072, CCTCC NO: C2019188.
3. Purification of monoclonal antibodies
Antibodies were purified from ascites fluid obtained in step 2 using HiTrap Protein G HP affinity chromatography as described. The purity of the antibody is identified by SDS-PAGE gel, the detection result is shown in figure 1, and a lane M is a Protein Marker in figure 1; lane 1 is unmodified IgG and lane 2 is denatured IgG (denaturation method is boiling purified sample for 5min, see the literature "preparation of Bt Cry1 toxoid monoclonal antibody and single chain antibody and activity analysis thereof, 2017" for details). It can be seen from FIG. 1 that the antibody is relatively pure. The concentration measured by an ultraviolet micro-spectrophotometer is 3.65mg/ml. Purified antibody was stored in aliquots at-80 ℃.
EXAMPLE 2 characterization of monoclonal antibodies
1. Subtype identification
The culture supernatant of the monoclonal antibody prepared in example 1 was assayed using an immunoglobulin ELISA kit 88-50660-22 purchased from Thermo, according to the instructions.
The results show that the heavy chain subtype of the monoclonal antibody of the invention is IgG1 type, and the light chain subtype is kappa type.
2. Monoclonal antibody reaction specificity
Cry1Aa, cry1Ab, cry1Ac, cry1B, cry1C, cry1F and Cry2A proteins are selected, and the recognition specificity of the monoclonal antibody is detected by an indirect ELISA method.
The indirect ELISA method was as follows:
1. coating: seven proteins were diluted to 2. Mu.g/ml with CBS buffer, coated at 100. Mu.l/well and incubated overnight at 4 ℃.
2. And (3) sealing: the next day the plates were washed 3 times with PBST. 200. Mu.l of 5% MPBS were added to each well and incubated at 37 ℃ for 1h.
3. Sample adding: PBST washing plate three times, each hole adding PBS diluted to the final concentration of 50 u g/ml antibody, 37 degrees C were incubated for 1h.
4. Adding an enzyme-labeled secondary antibody: PBST was washed three times, and a 5000-fold dilution of enzyme-labeled secondary antibody (HRP-goat anti-mouse antibody) with 2% MPBS was added to the wells of the plate at 100. Mu.L/well, and incubated at 37 ℃ for 1 hour.
5. Color development: PBST washing plate 5 times, adding single component TMB color developing solution into the micro-hole of the ELISA plate, 100 μ l/hole, and incubating for 15min in the incubator at 37 ℃.
6. Reading: with 2MH 2 SO 4 The reaction was stopped, 50. Mu.l/well and absorbance was read at 450nm with a microplate reader. It can be seen that the reaction of the sample containing the Cry2A protein appeared clearA blue color change was observed and the OD value was high.
As shown in fig. 2, it can be seen that the 1D2D11 monoclonal antibody obtained in example 1 has a lower specific reaction on Cry1B, but not on Cry1Aa, cry1Ab, cry1Ac, cry1C, or Cry1F, indicating that the monoclonal antibody has better specificity.
EXAMPLE 3 establishment of monoclonal antibodies DAS-ELISA detection
1. The samples were analyzed by chessboard titration (Lorenzen N, olesen N J,
Figure GDA0003898583010000061
determination of optimal antibody concentrations in the cells and fish by monoclonal antibodies to the viral G protein.1990) by
(1) Coating capture antibody: the Cry2A toxin polyclonal antibody (the preparation method is referred to as the preparation and application analysis of the canine procalcitonin protein polyclonal antibody, 2019') is sequentially diluted to 0.1, 0.5, 1, 2 and 5 mu g/m by using a PBS buffer solution, added into a 96-well enzyme label plate, added into the plate at 100 mu l/well and kept at 4 ℃ overnight.
(2) And (3) sealing: the next day the plates were washed 3 times with PBST. 200 μ l of 5% MPBS was added to each well and incubated at 37 ℃ for 1h.
(3) Adding the antibody to be detected: PBST plates were washed three times, and 100. Mu.l of Cry2A monoclonal antibody (concentration: 0.1, 0.5, 1, 2, 5. Mu.g/ml) diluted with PBS was added to each well in a checkerboard format, and incubated at 37 ℃ for 1h in an incubator.
(4) Adding an enzyme-labeled antibody: the plates were washed 3 times with PBST, and 100 μ Ι hrp-labeled goat anti-mouse antibody (1.
(5) Color development: PBST washing plate 5 times, adding TMB color solution into ELISA plate micropore, 100 μ l/hole, and placing in 37 deg.C incubator to incubate for 15min.
(6) Reading: with 2MH 2 So 4 The reaction was stopped, 50. Mu.l/well and absorbance was read at 450nm with a microplate reader.
In this example, the optimum concentrations of the capture antibody and the detection antibody determined from the range of momentum change for establishing the standard curve are determined as 0.5. Mu.g/ml and 0.5. Mu.g/ml, respectively, as shown in FIG. 3 (taking the optimum capture antibody assay as an example).
DAS-ELISA procedure
(7) Coating the capture antibody: the polyclonal antibody against Cry2A toxin was diluted to 0.5. Mu.g/ml with PBS buffer, added to a 96-well microplate at 100. Mu.l/well and overnight at 4 ℃.
(8) And (3) sealing: the next day the plates were washed 3 times with PBST. 200. Mu.l of 5% MPBS were added to each well and incubated at 37 ℃ for 1h.
(9) Adding a sample: PBST plates were washed three times, cry2A toxin was dissolved in CBS buffer and diluted 2 fold and added to wells at 100. Mu.l/well with CBS as a blank and incubated for 1h at 37 ℃.
(10) Adding the antibody to be detected: the PBST plates were washed three times, 0.5. Mu.g/ml Cry2A monoclonal antibody (100. Mu.l/well) was added to the wells, and incubated for 1h at 37 ℃.
(11) Adding an enzyme-labeled antibody: the plates were washed 3 times with PBST, and 100 μ Ι hrp-labeled goat anti-mouse antibody (1.
(12) Color development: PBST washing plate 5 times, adding single component TMB color developing solution into the micro-hole of the ELISA plate, 100 μ l/hole, and incubating for 15min in the incubator at 37 ℃.
(13) Reading: with 2MH 2 SO 4 The reaction was stopped, 50. Mu.l/well and absorbance was read at 450nm using a microplate reader.
The minimum Limit of detection (LOD) is defined as the blank control value. + -. 5X standard deviation, in this case the LOD value is 0.010763. The minimum Limit of quantitation (LOQ) is defined as the blank. + -. 10 standard deviation. The LOQ value in this case is 0.020702. In DAS-ELISA, the optimal concentrations of capture antibody and detection antibody were determined to be 0.5 and 0.5. Mu.g/ml, respectively. According to the lowest detection limit and the visual detection range, the quantitative detection range is 0.010763-4 mug/ml (if the detection range is exceeded, the result may be inaccurate).
After parameter fitting, a standard curve is obtained as shown in fig. 4:
standard curve equation: y = (A-D)/[ 1+ (x/C) ^ B]+ D, wherein a =3.03818, B = -0.87429, C =0.53720, D =0.19353.r is 2 =0.99743。
3. DAS-ELISA specificity assay
Cry1Aa, cry1Ab, cry1Ac, cry1B, cry1C and Cry1F are detected by the established DAS-ELISA method to verify the specificity of the established method (Cry 1B is taken as an example in the embodiment for carrying out cross reaction detection).
(1) Coating capture antibody: the polyclonal antibody of the Cry2A toxin is diluted to 0.5 mu g/ml by PBS buffer solution, added into a 96-well enzyme label plate at 100 mu l/well and stays overnight at 4 ℃.
(2) And (3) sealing: the next day the plates were washed 3 times with PBST. 200. Mu.l of 5% MPBS were added to each well and incubated at 37 ℃ for 1h.
(3) Adding a sample: PBST plates were washed three times, cry1B toxin was dissolved in CBS buffer and diluted 2 fold and added to wells at 100. Mu.l/well with CBS as a blank and incubated for 1h at 37 ℃.
(4) Adding the antibody to be detected: the PBST was washed three times, 0.5. Mu.g/ml Cry2A monoclonal antibody (100. Mu.l/well) was added to the wells, and incubated for 1h at 37 ℃ in an incubator.
(5) Adding an enzyme-labeled antibody: the plates were washed 3 times with PBST, and 100 μ Ι hrp-labeled goat anti-mouse antibody (1.
(6) Color development: PBST washing plate 5 times, adding TMB color solution into ELISA plate micropore, 100 μ l/hole, and placing in 37 deg.C incubator to incubate for 15min.
(7) Reading: with 2MH 2 So 4 The reaction was stopped, 50. Mu.l/well and absorbance was read at 450nm with a microplate reader.
The cross reaction result of the Cry2A and the DAS-ELISA method established by taking Cry1B toxin as an example is shown in fig. 5, and it can be seen that the cross reaction rate of the DAS-ELISA method established in the present embodiment to Cry1B is 3.2%. The cross-reactivity rates with other proteins (Cry 1Aa, cry1Ab, cry1Ac, cry1C and Cry1F with 50 μ g/ml) are all less than 0.1%. The detection method is proved to have stronger specificity and can be used for single detection of Cry 2A.
4. Addition recovery experiment
The crushed rice, corn and soybean (10 g/part) are weighed into a 50ml centrifuge tube, and 10ng/g, 50ng/g and 100ng/g of standard BtCry2A toxin are respectively added into the centrifuge tube. The sample was shaken at room temperature for 30min and then placed in a refrigerator at 4 ℃ overnight. The next day, 10ml of CBS buffer containing 0.05% Tween-20 was added to the sample and extracted with shaking at room temperature for 2h. Subsequently, the mixture was centrifuged at 3000rpm for 10min, and the supernatant was diluted ten-fold with CBS and used directly for the double antibody sandwich ELISA assay. Blank control is a sample without added toxin. The results are shown in Table 1.
TABLE 1 additive recovery test
Figure GDA0003898583010000091
As can be seen from table 1, the addition recovery rate of the detection method provided by the embodiment is between 85% and 105.4%, and the coefficient of variation is less than 8.4%, which indicates that the established method has better accuracy and can be used for quantitative detection of Cry2A toxin in agricultural products.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and amendments can be made without departing from the principle of the present invention, and these modifications and amendments should also be considered as the protection scope of the present invention.

Claims (5)

1. A hybridoma cell strain secreting a Bacillus thuringiensis Cry2A monoclonal antibody has a preservation number of CCTCC NO: C2019188.
2. the hybridoma cell line of claim 1 secreting the bacillus thuringiensis Cry2A monoclonal antibody obtained.
3. The application of the Bacillus thuringiensis Cry2A monoclonal antibody obtained by the secretion of the hybridoma cell strain according to claim 1 in Cry2A toxin detection.
4. The application as claimed in claim 3, characterized by the specific steps of:
1) Diluting the Cry2A toxin polyclonal antibody to 0.5 mug/ml by using PBS buffer solution, adding the diluted polyclonal antibody into an ELISA plate, and keeping the diluted polyclonal antibody at 100 mug/hole overnight at 4 ℃; washing the plate with PBST the next day, adding MPBS, and incubating for 1h; after PBST washing, diluting a sample to be detected by CBS buffer solution, adding the sample to the ELISA plate at 100 mu l/hole, and incubating for 1h by taking CBS as a blank control;
2) Washing the plate by PBST, adding 0.5 mug/ml Cry2A monoclonal antibody into the hole, incubating for 1h at 100 mug/hole; after PBST plate washing, 100. Mu.l of HRP-labeled goat anti-mouse antibody is added into each hole, and incubation is carried out for 1h;
the Cry2A monoclonal antibody is prepared from a Cry2A monoclonal antibody with the preservation number of CCTCC NO: c2019188 hybridoma cell strain;
3) PBST washing a plate, adding TMB developing solution into micropores of an ELISA plate at 100 mu l/hole, and placing the plate in an incubator at 37 ℃ for incubation for 15min; if blue color appears, the sample to be detected contains Cry2A toxin.
5. A Cry2A toxin detection kit comprising a Bacillus thuringiensis Cry2A monoclonal antibody, wherein the Bacillus thuringiensis Cry2A monoclonal antibody is prepared from a monoclonal antibody with a preservation number of CCTCC NO: c2019188.
CN202010350203.9A 2020-04-28 2020-04-28 Monoclonal antibody of bacillus thuringiensis Cry2A toxin and application thereof Active CN111363722B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010350203.9A CN111363722B (en) 2020-04-28 2020-04-28 Monoclonal antibody of bacillus thuringiensis Cry2A toxin and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010350203.9A CN111363722B (en) 2020-04-28 2020-04-28 Monoclonal antibody of bacillus thuringiensis Cry2A toxin and application thereof

Publications (2)

Publication Number Publication Date
CN111363722A CN111363722A (en) 2020-07-03
CN111363722B true CN111363722B (en) 2022-11-22

Family

ID=71205748

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010350203.9A Active CN111363722B (en) 2020-04-28 2020-04-28 Monoclonal antibody of bacillus thuringiensis Cry2A toxin and application thereof

Country Status (1)

Country Link
CN (1) CN111363722B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105198990B (en) * 2015-10-12 2018-10-30 江苏省农业科学院 Antibody and the preparation method and application thereof for the detection of Bt Cry1 toxoid wide spectrums
CN105693856A (en) * 2016-04-25 2016-06-22 江苏省农业科学院 Monoclonal antibody, cell strain secreting monoclonal antibody, preparation method and application
CN110018310A (en) * 2019-03-18 2019-07-16 中国农业科学院生物技术研究所 The enzyme linked immunological kit of quantitative detection insect resistance protein Cry2A
CN113481170A (en) * 2019-03-18 2021-10-08 中国农业科学院生物技术研究所 Hybridoma cell strain, antibody produced by hybridoma cell strain and preparation method of antibody

Also Published As

Publication number Publication date
CN111363722A (en) 2020-07-03

Similar Documents

Publication Publication Date Title
US9371394B2 (en) Monoclonal antibodies and detection methods for phosphinothricin-N-acetyl-transferase enzyme
Charlermroj et al. Multiplex detection of plant pathogens using a microsphere immunoassay technology
Qiu et al. Phage-mediated competitive chemiluminescent immunoassay for detecting Cry1Ab toxin by using an anti-idiotypic camel nanobody
Zhao et al. Application of phage-display developed antibody and antigen substitutes in immunoassays for small molecule contaminants analysis: A mini-review
CN101042403A (en) ELISA kit for detecting EPSPS gene in herbicide-tolerance soybeans and method of use thereof
KR102154628B1 (en) Simultaneous diagnostic method for the Ralstonia Solanacearum and Fusarium Oxysporum using semi-quantitative lateral flow immunoassay
CN113024641A (en) Novel recombinant S protein of coronavirus, preparation method and application thereof
Qiu et al. Phage-displayed nanobody based double antibody sandwich chemiluminescent immunoassay for the detection of Cry2A toxin in cereals
CN108291233B (en) Compositions and methods for protein detection
CN102533663B (en) Foot-and-mouth disease hybridoma cell line, monoclonal antibody, detection reagent and test kit
CN111363722B (en) Monoclonal antibody of bacillus thuringiensis Cry2A toxin and application thereof
CN111337687A (en) Enzyme-linked immunosorbent assay quantitative detection kit for content of insect cadherin and use method thereof
CN116120459A (en) Anti-human IgE nano antibody and preparation method and application thereof
CN114280306B (en) ELISA detection kit and detection method for eleusine indica EPSPS protein
CN105777899B (en) anti-Bt Cry1Ab toxin monoclonal antibody, cell strain for generating antibody, preparation method and application
CN110607282B (en) Bovine parvovirus monoclonal antibody and application thereof in detecting bovine parvovirus infection
WO2021218053A1 (en) Variable region sequence of specific anti-clothianidin antibody, and preparation and application of anti-clothianidin recombinant intact antibody
Wang et al. Isolation of a peptide from Ph. D.-C7C phage display library for detection of Cry1Ab
DK3129403T3 (en) Antibody to HT-2-toxin-HT-2-toxin-antibody complex
CN109265395B (en) Preparation method and application of quinclorac hapten and antigen
CN108486065B (en) Secrete hybridoma cell strain and its monoclonal antibody application of anti-Rice Gall Dwarf In Guangdong Province monoclonal antibody
Kamle et al. Development of an enzyme-linked immunosorbent assay for the detection of GM proteins in transgenic crops/produce
US11841366B2 (en) Compositions and methods for detection of wild type cry protein and a hybrid cry protein
KR102385330B1 (en) Simultaneous diagnostic method and Simultaneous diagnostic kit for the Erwinia Carotovora and Phytophthora Infestans in soil using semi-quantitative lateral flow immunoassay
AU2015253560B2 (en) Monoclonal antibodies specific for Cry1Ca and related detection methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant